Sun Pharmaceutical Industries Limited has filed its quarterly confirmation certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The regulatory submission demonstrates the company's continued compliance with securities market regulations.

Regulatory Compliance Filing

The company submitted the confirmation certificate dated April 03, 2026, pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. The certificate was received from MUFG Intime India Private Limited, which serves as the company's registrar and share transfer agent.

Certificate Confirmation

MUFG Intime India Private Limited confirmed that securities received from depository participants for dematerialization during the quarter ended March 31, 2026, were properly processed according to regulatory requirements. The registrar verified that:

• Securities received for dematerialization were confirmed or rejected to depositories within prescribed timelines
• Security certificates were mutilated and cancelled after due verification
• Depositories' names were substituted in the register of members as registered owners
• All securities comprised in the certificates have been listed on relevant stock exchanges

Corporate Governance

The filing was signed by Anoop Deshpande, Company Secretary and Compliance Officer of Sun Pharmaceutical Industries Limited. The submission was made to National Stock Exchange of India Limited and BSE Limited, ensuring comprehensive regulatory compliance across all relevant market infrastructure institutions.

This quarterly filing represents part of the company's ongoing regulatory obligations and demonstrates adherence to SEBI's depositories regulations framework.

Sun Pharma Advanced Research Company Limited has formally notified stock exchanges about the resignation of a senior management personnel. The company informed the National Stock Exchange of India and BSE Limited on April 03, 2026, regarding the departure of Dr. Shravanti Bhowmik from her executive position.

Resignation Details

Dr. Shravanti Bhowmik, who served as Head of Operations Management and was a member of the Senior Management Team, resigned from her position effective from the close of business hours on March 31, 2026. The resignation was communicated to the company through a formal letter dated March 26, 2026.

Regulatory Compliance

The intimation was made under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Kajal Damania signed the formal communication to both stock exchanges, ensuring compliance with mandatory disclosure requirements for senior management changes.

Transition to Group Company

In her resignation letter, Dr. Bhowmik indicated that her departure stems from a transition to a new opportunity within the group company. She expressed her intention to continue professional growth while contributing to the broader organizational goals. The executive acknowledged the support and guidance received during her tenure, describing her experience as enriching while working with the dedicated team.

Professional Acknowledgment

Dr. Bhowmik's resignation letter reflected appreciation for the opportunities and trust extended to her during her role as VP - Operations Management. She expressed commitment to staying connected and continuing to contribute to the overall success of the group, indicating a positive transition within the organizational structure.